We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.00 | -9.52% | 47.50 | 45.00 | 50.00 | 52.50 | 47.50 | 52.50 | 48,162 | 14:43:07 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Electronic Computers | 1.03M | -2.92M | -0.2188 | -2.17 | 7M |
From Oct 2019 to Oct 2024
TIDMFDBK
RNS Number : 4153H
Feedback PLC
30 November 2015
30 November 2015
Feedback plc
("Feedback" or the "Company")
Result of AGM
The Company announces that at the annual general meeting of the Company held earlier today, all resolutions proposed were duly passed.
For further information contact:
Feedback plc Tel: 01954 718072 Tom Charlton /Trevor Brown/ Mike Hayball Sanlam Securities UK (Nominated Tel: 020 7628 Adviser and Joint Broker) 2200 Simon Clements / Virginia Bull Peterhouse Corporate Finance Ltd Tel: 020 7469 (Joint Broker) 0936 Lucy Williams / Duncan Vasey
Notes to editors:
TexRAD is a novel sophisticated imaging risk stratification research tool that analyses the textures in existing radiological scans. This research software application analyses textures, detecting and measuring tumour heterogeneity (complexity) from these images, revealing more information from medical images than is readily visible to the naked eye. Research to date has shown that TexRAD could potentially assist the clinician (as an 'Imaging Biomarker') in confident decision-making: it has the potential to assess the prognosis, disease-severity (e.g. risk of metastases) and response evaluation of patients with cancer. Currently TexRAD research has shown great potential in many different oncological sites, including, colorectal, breast, lung, prostate, oesophageal, head & neck, lymphoma, liver and renal cancers and could potentially be employed as a heterogeneity assessing tool in the era of 'Precision and Personalized Medicine'. TexRAD is manufactured under licence by company Cambridge Computed Imaging Ltd, a subsidiary of Feedback plc. More information is available on www.fbk.com and www.texrad.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGZBLFXEFFEFBQ
(END) Dow Jones Newswires
November 30, 2015 09:59 ET (14:59 GMT)
1 Year Feedback Chart |
1 Month Feedback Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
